ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma, Systemic"

  • Abstract Number: 2037 • ACR Convergence 2020

    Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts

    Anastasiya Muntyanu1, Bina Kassamali2, Ruth Ann Vleugels3 and Avery LaChance3, 1McGill University, Montreal, QC, Canada, 2Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…
  • Abstract Number: 1171 • ACR Convergence 2020

    Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests. Results from the Juvenile Scleroderma Inception Cohort

    Ivan Foeldvari1, Bernd Hinrichs2, Kathryn Torok3, Maria Jose Santos4, Ozgur Kasapcopur5, Amra Adrovic6, Valda Stanevicha7, Flavio Sztajnbok8, Maria Teresa Terreri9, Ana Paula Sakamoto10, Ekaterina Alexeeva11, Jordi Anton12, Maria Katsicas13, Vanessa Smith14, Tadej Avcin15, Edoardo Marrani16, Mikhail Kostik17, Thomas Lehman18, Walter Alberto Sifuentes-Giraldo19, Simone Appenzeller20, Mahesh Janarthanan21, Monika Moll22, Dana Nemcova23, Dieneke Schonenberg-Meinema24, Cristina Battagliotti25, Lillemor Berntson26, Blanca Bica27, Jürgen Brunner28, Patricia Costa Reis29, Despina Eleftheriou30, Liora Harel31, Gerd Horneff32, Tilmann Kallinich33, Dragana Lazarevic34, Kirsten Minden35, Susan Nielsen36, Farzana Nuruzzaman37, Anjali Patwardhan38, Yosef Uziel39 and Nicola Helmus40, 1Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 2Kinderklinik Heidberg Pulmologie, Hamburg, Germany, 3University of Pittsburgh, Pittsburgh, PA, 4Hospital Garcia de Orta, Almada, Portugal, 5PRINTO, Istituto Giannina Gaslini, Genova, Italy, 6Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, 7Riga Stradins University, Riga, Latvia, 8Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 9Federal University of São Paulo, São Paulo, Brazil, 10UNIFESP, Sao Paulo, Brazil, 11Scientific Center of Children’s Health of RAMS, Moscow, Russia, 12Sant Joan de Déu Hospital, Madrid, Spain, 13Hospital de Pediatria, Buenos Aires, Argentina, 14Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, 15Ljubljana University Medical Centre, Ljubljana, Slovenia, 16University of Florence, Firenze, Italy, 17Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 18Hospital for Special Surgery, New York, 19Hospital Universitario Ramon y Cajal, Madrid, Spain, 20Unicamp, Campinas, Brazil, 21Sri Ramachandra University, Chennai, India, 22University of Tübingen, Tübingen, Germany, 23General University Hospital, Prague, Czech Republic, 24Amsterdam UMC, Amsterdam, Netherlands, 25Children's Hospital Dr. Orlando Alassia, Santa Fee, Argentina, 26Uppsala University Hospital, Uppsala, Sweden, 27Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ), Rio de Janeiro, Brazil, 28Tirol Kliniken, Innsbruck, Innsbruck, Austria, 29Hospital de Santa Maria, Lisbon, Portugal, 30Great Ormond Street Hospital, London, United Kingdom, 31Clalit Health Services, Nettnja, Israel, 32Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 33Charite, Berlin, Germany, 34KC Niš, Nis, Serbia, 35Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 36Rigshospitalet, Copenhagen, Denmark, 37Stony Brook Children's Hospital, Stony Brook, NY, 38University of Missouri, Columbia, 39Meir Medical Center, Kfar Saba, Israel, 40Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

    Background/Purpose: Juvenile systemic sclerosis (jSSc) has a prevalence in around 3 in a million children. Pulmonary involvement occurs in approximately 40 % in the international…
  • Abstract Number: 2042 • ACR Convergence 2020

    A Low FODMAP Diet Is Not Associated with Decreased GI Symptoms or Changes in GI Microbial Composition in Patients with Systemic Sclerosis

    Natalie Howlett1, Sungeun Lee1, Venu Lagishetty1, Zsuzsanna McMahan2, Meifang Wu1, Jonathan Jacobs1 and Elizabeth Volkmann3, 1University of California, Los Angeles, Los Angeles, 2Johns Hopkins University, Baltimore, 3University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Dietary restriction of short-chain fermentable oligosaccharides, disaccharides, monosaccharides and polyols (low FODMAP) has been found to reduce GI symptoms in patients with IBS and…
  • Abstract Number: 0383 • ACR Convergence 2020

    Sex Differences in Severity and Progression of Interstitial Lung Disease in Systemic Sclerosis: What We Have Learned from Clinical Trials

    Elizabeth Volkmann1, Ning Li2, Michael Roth2, Carol Feghali-Bostwick3, Richard Silver4, DeAnna Baker Frost5, Shervin Assassi6, Grace Kim2, Jonathan Goldin2 and Donald Tashkin2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles, 3The Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, 5The Medical University of South Carolina, Charleston, 6University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Although systemic sclerosis (SSc) disproportionately affects females compared with males [1], observational studies have demonstrated higher mortality rates in males with SSc [2]. This…
  • Abstract Number: 1172 • ACR Convergence 2020

    Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma

    Gloria Lanzoni1, Giorgia Martini1, Alessandra Meneghel1, Fabio Vittadello2, Biagio Castaldi1, Elisabetta Zanatta3 and Francesco Zulian1, 1Department of Woman's and Child's Health, University of Padova, Padua, Italy, 2Centro Studi Statistici Explora, Padua, Italy, 3Department of Medicine-DIMED, University of Padova, Padua, Italy

    Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare condition in childhood and its variety with no skin involvement, systemic sclerosis sine scleroderma (JSSSS) is anecdotal…
  • Abstract Number: 0384 • ACR Convergence 2020

    Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease

    Nancy Wareing1, Ning Li2, Elizabeth Volkmann3, Marka Lyons4, Michael Roth2, Donald Tashkin2 and Shervin Assassi1, 1University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 2University of California, Los Angeles, Los Angeles, 3University of California, Los Angeles, Los Angeles, CA, 4University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

    Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature.  However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This…
  • Abstract Number: 1173 • ACR Convergence 2020

    No Disease Progression After 36 Months Follow up in the Juvenile Systemic Scleroderma Inception Cohort

    Ivan Foeldvari1, Jens Klotsche2, Ozgur Kasapcopur3, Amra Adrovic4, Maria Teresa Terreri5, Edoardo Marrani6, Tadej Avcin7, Maria Katsicas8, Dana Nemcova9, Maria Jose Santos10, Jürgen Brunner11, Tilmann Kallinich12, Mikhail Kostik13, Kirsten Minden14, Anjali Patwardhan15, Kathryn Torok16 and Nicola Helmus17, 1Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 2German Rheumatism Research Center, Berlin, Germany, 3PRINTO, Istituto Giannina Gaslini, Genova, Italy, 4Cerrahpaşa Tıp Fakültesi, Istanbul, Turkey, 5Federal University of São Paulo, São Paulo, Brazil, 6University of Florence, Firenze, Italy, 7Ljubljana University Medical Centre, Ljubljana, Slovenia, 8Hospital de Pediatria, Buenos Aires, Argentina, 9General University Hospital, Prague, Czech Republic, 10Hospital Garcia de Orta, Almada, Portugal, 11Tirol Kliniken, Innsbruck, Innsbruck, Austria, 12Charite, Berlin, Germany, 13Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 14Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 15University of Missouri, Columbia, 16University of Pittsburgh, Pittsburgh, PA, 17Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

    Background/Purpose: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. Longitudinal prospective follow up data of…
  • Abstract Number: 0392 • ACR Convergence 2020

    Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years

    Janet Pope1, Kobina Quansah2, Martin Kolb3, Jason Flavin4, Hassan Shazia5 and Soo Jin Seung5, 1Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 2Boehringer Ingelheim (Canada) Limited, Burlington, ON, Canada, 3McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada, 4Boehringer Ingelheim, Corporate Headquarters, Burlington, ON, Canada, 5HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin thickening, vascular lesions and fibrotic changes in various organs, mainly the lungs, heart, intestinal…
  • Abstract Number: 1384 • ACR Convergence 2020

    Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis

    Sophie Liem1, Nina van Leeuwen2, Thea Vliet Vlieland3, Lian de Pundert4, Rita Schriemer5, Julia Spierings6, Madelon Vonk7 and Jeska de Vries-Bouwstra1, 1Leiden University Medical Center, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3Leiden University Medical Center, 2300 RC Leiden, Netherlands, 4HAGA Hospital, The Hague, Netherlands, 5NVLE, Utrecht, 6University Medical Center Utrecht, Maastricht, Netherlands, 7Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands

    Background/Purpose: The importance of non-pharmacologic interventions in systemic sclerosis (SSc) is increasingly recognized. Physical therapy is among the most frequently used interventions, but knowledge on…
  • Abstract Number: 0394 • ACR Convergence 2020

    Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors

    Guanying Wang1, Diane Mar2, Joy Wu3, Julia Simard4, Rita Popat1 and Lorinda Chung5, 1Department of Epidemiology & Population Health, Stanford University School of Medicine, Palo Alto, CA, 2Stanford Department of Immunology/Rheumatology, Palo Alto, CA, 3Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Palo Alto, CA, 4Stanford Medicine, Stanford, CA, 5Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA

    Background/Purpose: This study aims to determine the prevalence of a diagnosis of osteopenia/osteoporosis (OP) in systemic sclerosis (SSc) patients and to identify the clinical and…
  • Abstract Number: 1385 • ACR Convergence 2020

    Physical Therapy in Patients with Systemic Sclerosis: The Perspective of Physical Therapists on Current Delivery and Educational Needs

    Sophie Liem1, Nina van Leeuwen2, Thea Vliet Vlieland3, Lian de Pundert4, Rita Schriemer5, Julia Spierings6, Madelon Vonk7 and Jeska de Vries-Bouwstra1, 1Leiden University Medical Center, Leiden, Netherlands, 2LUMC, Leiden, Netherlands, 3Leiden University Medical Center, 2300 RC Leiden, Netherlands, 4HAGA Hospital, The Hague, Netherlands, 5NVLE, Utrecht, 6University Medical Center Utrecht, Maastricht, Netherlands, 7Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands

    Background/Purpose: As there is currently no cure available for systemic sclerosis (SSc), nonpharmacologic care is an essential element in the management of the disease. Physical…
  • Abstract Number: 0402 • ACR Convergence 2020

    Optical Coherence Tomography of the Skin Detects Scleroderma Changes in Clinically Unaffected Skin: An Opportunity for Early Detection of Systemic Sclerosis

    Giuseppina Abignano1, Duygu Temiz Karadag2, Ozcan Gundogdu3, Giovanni Lettieri4, Maria Carmela Padula5, Angela A Padula5, Paul Emery6, Salvatore D'Angelo5 and Francesco Del Galdo6, 1Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Potenza, Italy, 2Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy and Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, Kocaeli, Turkey, 3Department of Biomedical Engineering, Kocaeli University, Kocaeli,Turkey, Kocaeli, Turkey, 4Radiology Department, San Carlo Hospital, Potenza, Italy, Potenza, Italy, 5Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy, Potenza, Italy, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: The Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) study has shown that more than 80% of patients with Raynaud’s Phenomenon, specific ANA positivity and…
  • Abstract Number: 1389 • ACR Convergence 2020

    Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease

    Cristina Hidalgo Calleja1, Concepción Román Curto2, Luis Gómez-Lechón3, Maria Elisa Acosta2, Olga Compán4, Sonia Pastor2, Carlos Montilla Morales2, Lucía Pantoja Zarza5, María Dolores Sánchez González6 and Lucía López Corral2, 1Hospital Universitario Salamanca, Salamanca, Spain, 2Hospital Universitario de Salamanca, Salamanca, Spain, 3Hospital Francesc de Borga de Gandía, Valencia, Spain, 4Hospital Universitario de Salamanca, ´Salamanca, Spain, 5Complejo Asistencial Hospital General de Segovia, Segovia, Spain, 6Hospital Clínico Universitario de Valladolid, Valladolid, Spain

    Background/Purpose: Chronic graft-vs-host disease (cGVHD) is a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT), typically occurring within three years post-transplant and affecting…
  • Abstract Number: 0916 • ACR Convergence 2020

    Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis

    Fiza Ahmed1, Svetlana Nihtyanova1, Stamatia Chatzinikolaou2, Voon Ong1, Charles Murray2 and Christopher Denton3, 1Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, 2Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, 3University College London, London, United Kingdom

    Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
  • Abstract Number: 1390 • ACR Convergence 2020

    Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample

    Atefeh Vafa1, Omid Behnamfar2 and Yih Chang Lin3, 1University of South Florida, Tampa, FL, 2University of California San Diego, La Jolla, CA, 3University of South Florida, Morsani College of Medicine, Tampa, FL

    Background/Purpose: Several systemic autoimmune rheumatic diseases have been shown to increase coronary artery disease (CAD) risk, notable rheumatoid arthritis and systemic lupus erythematosus.  However, data…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology